## GeneDx (GeneDx Holdings Corp.) — a filings-first deep dive (with the “hard-to-find” stuff) **Executive takeaway:** GeneDx’s disclosed “moat” is less about a single test and more about (1) an internally built rare-disease knowledgebase/dataset (phenotype + trio structure) and (2) operational + reimbursement plumbing (portfolio-based revenue recognition, variable consideration, and payor-specific friction) that determines whether sequencing volume becomes durable cash flow. ["over 6 million structured phenotypes"](0001818331-25-000021|0) ["processed as parent-child trios"](0001818331-25-000021|0) ["updates estimated variable consideration quarterly"](0001818331-23-000064|0) --- ## 0) Quick “map” (jump-to sections) 1. **What GeneDx actually sells (in filings terms)** 2. **The “dataset moat” disclosed in 10-K (and why it’s hard to replicate)** 3. **Revenue mechanics that matter: payor mix, variable consideration, and reserve releases** *(filings gold)* 4. **Who really pays? Payor concentration + A/R signals** *(hard to find)* 5. **Regulatory stack: CLIA/CAP/state licensing + the FDA LDT rule timeline** *(hard to operationalize)* 6. **M&A/accounting tells: what they paid for in the GeneDx acquisition (intangible composition)** 7. **Most recent disclosed trajectory: preliminary FY2025 + FY2026 guide (8-K exhibit)** --- ## 1) What GeneDx “is” in filings language (what they do + who they bill) GeneDx describes itself as providing “genomics-related diagnostic and information services,” generating test reports for clinicians/patients and billing “third-party payors across the United States.” ["genomics-related diagnostic"](0001818331-23-000064|0) ["bills third-party payors"](0001818331-23-000064|0) In the more recent 10-K framing, their core commercialization thesis is that **exome/genome sequencing can replace “fragmented” panel testing** (they literally position WGS as “Just One Test”). ["repeated and fragmented testing"](0001818331-25-000021|0) ["Just One Test"](0001818331-25-000021|0) --- ## 2) The dataset moat — the *specific* disclosures worth noticing ### The two numbers that matter GeneDx discloses a dataset with: - **“over 6 million structured phenotypes”** and - **~60% of exomes/genomes processed as “parent-child trios.”** ["over 6 million structured phenotypes"](0001818331-25-000021|0) ["approximately 60%"](0001818331-25-000021|0) ["parent-child trios"](0001818331-25-000021|0) Why that’s unusually meaningful (and easy to miss in filings): - **Trio structure** is not just “more data”; it changes interpretability (you can infer inheritance patterns, de novo variants, etc.). GeneDx explicitly says they invested in sequencing parents because it can “provide additional diagnostic information” and “improv[e] the precision” of analysis. ["sequence the parents"](0001818331-25-000021|0) ["additional diagnostic information"](0001818331-25-000021|0) ["improving the precision"](0001818331-25-000021|0) ### The Medicaid angle (often overlooked) GeneDx claims it has “served the Medicaid population for nearly a decade ahead of the first state to enact health coverage for exome/genome,” using that to argue the dataset is “highly diversified” and matches U.S. demographics. ["served the Medicaid population"](0001818331-25-000021|0) ["highly diversified"](0001818331-25-000021|0) This is strategically important because payer mix affects: - **collections, denials, and retroactive adjustments** (see §3), and - whether “volume growth” translates into “revenue quality.” --- ## 3) Revenue mechanics that matter (and are genuinely “hard to find”) ### 3.1 Disaggregated revenue by payor channel (Q2’23 + 6M’23) Below is a filings-sourced view of how revenue breaks out (this kind of table often gets ignored, but it’s the skeleton of the business model). **Disaggregated revenue by payor category (USD millions)** | Period | Patients w/ third‑party insurance | Institutional customers | Self‑pay patients | Other revenue | Total | |---|---:|---:|---:|---:|---:| | **Q2 2023** | 30.573 ["30,573"](0001818331-23-000064|0) | 15.748 ["15,748"](0001818331-23-000064|0) | 0.314 ["314"](0001818331-23-000064|0) | 2.071 ["2,071"](0001818331-23-000064|0) | 48.706 ["48,706"](0001818331-23-000064|0) | | **Q2 2022** | 21.398 ["21,398"](0001818331-23-000064|0) | 11.120 ["11,120"](0001818331-23-000064|0) | 1.486 ["1,486"](0001818331-23-000064|0) | 2.165 ["2,165"](0001818331-23-000064|0) | 36.169 ["36,169"](0001818331-23-000064|0) | | **6M 2023** | 55.902 ["55,902"](0001818331-23-000064|0) | 31.808 ["31,808"](0001818331-23-000064|0) | 0.775 ["775"](0001818331-23-000064|0) | 3.360 ["3,360"](0001818331-23-000064|0) | 91.845 ["91,845"](0001818331-23-000064|0) | | **6M 2022** | 68.860 ["68,860"](0001818331-23-000064|0) | 15.151 ["15,151"](0001818331-23-000064|0) | 2.488 ["2,488"](0001818331-23-000064|0) | 3.611 ["3,611"](0001818331-23-000064|0) | 90.110 ["90,110"](0001818331-23-000064|0) | **What’s “hard” here:** In many diagnostics businesses, “revenue” is not the same as “cash collected,” and the mix between third‑party, institutional, and self‑pay typically drives days sales outstanding, denial work, and how much “true-up” revenue you see later. GeneDx effectively confirms this by explicitly pointing to the role of payor mix, reimbursement policies, collection history, and price concessions in diagnostic test revenue. ["depends on a number of factors"](0001818331-23-000064|0) ["payor mix"](0001818331-23-000064|0) ["historical collection experience"](0001818331-23-000064|0) ### 3.2 The hidden lever: “variable consideration” + quarter-to-quarter true-ups GeneDx says it determines transaction price **“on a portfolio basis when applicable”** and **updates estimated variable consideration quarterly**—this is a big deal because it means **reported revenue includes modeled/estimated reimbursement outcomes** that can later reverse. ["portfolio basis"](0001818331-23-000064|0) ["updates estimated variable consideration quarterly"](0001818331-23-000064|0) They disclose that in **Q2 2023** the quarterly change in estimate produced a **net $3.5 million increase to revenue** for tests whose performance obligation was satisfied in prior periods, tied to **“partial release of a third party payor reserve.”** ["net $3.5 million increase"](0001818331-23-000064|0) ["partial release"](0001818331-23-000064|0) ["payor reserve"](0001818331-23-000064|0) They also disclose the opposite case: **Q2 2022 had a net $30.1 million decrease** for prior-period tests, with **$24.2 million related to years ended Dec 31, 2021 and prior**—a very explicit signal that reimbursement/accounting adjustments can be *material* and can reach back multiple years. ["$30.1 million decrease"](0001818331-23-000064|0) ["$24.2 million"](0001818331-23-000064|0) ["December 31, 2021"](0001818331-23-000064|0) ### 3.3 “Certain payor matters” (the section many readers skip, but investors shouldn’t) GeneDx states that third‑party payors (including government programs) may deny payment or seek recoupment for tests they argue were improperly billed / not medically necessary / against coverage determinations, and that revenue may be “subject to retroactive adjustment.” ["seek to recoup"](0001818331-23-000064|0) ["subject to retroactive adjustment"](0001818331-23-000064|0) They also disclose a concrete remediation step: **in Q3 2022 they instituted a third‑party review of billing claims and compliance practices**, plus new policies/procedures and strengthening the billing compliance team. ["third-party review"](0001818331-23-000064|0) ["billing compliance"](0001818331-23-000064|0) --- ## 4) Who really pays? Payor concentration + receivables signals GeneDx defines “significant” payors as those >10% of revenue or A/R, and then actually provides a payor concentration table (with anonymized payors). ["represent more than 10%"](0001818331-23-000064|0) ### Payor concentration snapshot (from filings; anonymized payors) | Payor | Q2’23 Revenue % | Q2’22 Revenue % | 6M’23 Revenue % | 6M’22 Revenue % | A/R % @ 6/30/23 | A/R % @ 12/31/22 | |---|---:|---:|---:|---:|---:|---:| | Payor B | 14% ["14%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 14% ["14%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 14% ["14%"](0001818331-23-000064|0) | | Payor C | *<10% ["*less than 10%"](0001818331-23-000064|0) | 12% ["12%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 10% ["10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | | Payor D | *<10% ["*less than 10%"](0001818331-23-000064|0) | 10% ["10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 10% ["10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | | Payor E | 28% ["28%"](0001818331-23-000064|0) | 19% ["19%"](0001818331-23-000064|0) | 26% ["26%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 15% ["15%"](0001818331-23-000064|0) | 14% ["14%"](0001818331-23-000064|0) | **Why this is a big analytical lever:** Payor E being **28% of quarterly revenue** is the kind of concentration that makes (a) contract terms, (b) medical policy shifts, and (c) audit behavior disproportionately impactful. ["Payor E"](0001818331-23-000064|0) ["28%"](0001818331-23-000064|0) ### A second “quiet” risk: supplier concentration The same filing discloses supplier concentration: **one supplier accounted for ~14% of purchases** (Q2’23 and 6M’23). ["One supplier accounted for approximately 14%"](0001818331-23-000064|0) That matters because lab operations are reagent- and instrument-dependent; supply disruption can hit turnaround time, COGS, and service levels. --- ## 5) Regulatory stack — what GeneDx must keep “green” to stay in business This is where filings give you operational truth (and where most casual research is weakest). ### 5.1 CLIA + CAP + state licensing (the must-have permissions) GeneDx states its laboratories are subject to **CLIA**, with requirements across operations/personnel/quality control and that CLIA is a prerequisite for billing Medicare/Medicaid and many commercial payors. ["subject to the Clinical Laboratory Improvement Amendments"](0001818331-25-000021|0) ["prerequisite to be eligible to bill"](0001818331-25-000021|0) They also disclose **CAP accreditation** at their Gaithersburg lab and that CMS relies on CAP surveys/inspections when CAP is the accrediting organization. ["accredited by the College of American Pathologists"](0001818331-25-000021|0) ["CMS does not perform"](0001818331-25-000021|0) State licensing: they explicitly list states where they maintain lab licenses, and highlight New York’s test‑specific approval requirement for LDTs. ["state laboratory licenses"](0001818331-25-000021|0) ["Maryland and in New York, California, Pennsylvania and Rhode Island"](0001818331-25-000021|0) ["approval on a test-specific basis"](0001818331-25-000021|0) ["New York Department of Health"](0001818331-25-000021|0) ### 5.2 The FDA’s LDT rule: a timeline investors can actually model GeneDx discloses that FDA published a **final rule on LDTs (April 29, 2024)** and lays out a **five‑phase plan** to end broad enforcement discretion over ~4 years, with key effective dates. ["April 29, 2024"](0001818331-25-000021|0) ["five stages"](0001818331-25-000021|0) **FDA LDT rule phase timeline (as GeneDx summarizes it)** | Phase | Effective date | What starts applying (high level) | |---|---|---| | Phase 1 | May 6, 2025 ["Phase 1 (effective May 6, 2025)"](0001818331-25-000021|0) | medical device adverse event reporting + correction/removal reporting + certain quality systems complaint handling ["adverse event"](0001818331-25-000021|0) | | Phase 2 | May 6, 2026 ["Phase 2 (effective May 6, 2026)"](0001818331-25-000021|0) | “all other device requirements” except remaining QSR + premarket review ["all other device requirements"](0001818331-25-000021|0) | | Phase 3 | May 6, 2027 ["Phase 3 (effective May 6, 2027)"](0001818331-25-000021|0) | remaining applicable quality system requirements ["all remaining applicable quality systems"](0001818331-25-000021|0) | | Phase 4 | Nov 6, 2027 ["Phase 4 (effective November 6, 2027)"](0001818331-25-000021|0) | premarket submissions for high‑risk tests (PMA) ["premarket submission requirements for high-risk tests"](0001818331-25-000021|0) | | Phase 5 | May 6, 2028 ["Phase 5 (effective May 6, 2028)"](0001818331-25-000021|0) | premarket submissions for moderate/low risk (de novo / 510(k)) ["moderate- and low-risk tests"](0001818331-25-000021|0) | GeneDx also flags that the rule “potentially extends enforcement discretion” for certain tests, explicitly including **LDTs approved by NY State DOH** and certain pre‑May 6, 2024 tests (with limitations). ["extends enforcement discretion"](0001818331-25-000021|0) ["approved by the New York State Department of Health"](0001818331-25-000021|0) ["first marketed prior to May 6, 2024"](0001818331-25-000021|0) **Why this matters:** This is an explicit roadmap for potential incremental compliance cost, process overhead, and possibly product rationalization—especially for companies whose menu is mostly LDTs. --- ## 6) The acquisition accounting tells: what they *actually bought* (intangible mix) From a 10‑Q disclosure, GeneDx provides the **Legacy GeneDx acquisition** purchase price allocation (a rare, very concrete look at what management believed the “value” was). **Legacy GeneDx acquisition — selected fair values (USD millions)** | Line item | Value | |---|---:| | Trade names & trademarks | 50.0 ["Trade names and trademarks"](0001818331-23-000064|0) | | Developed technology | 48.0 ["Developed technology"](0001818331-23-000064|0) | | Customer relationships | 98.0 ["Customer relationships"](0001818331-23-000064|0) | | Goodwill | 185.871 ["Goodwill"](0001818331-23-000064|0) | | Aggregate purchase price | 364.476 ["Aggregate purchase price"](0001818331-23-000064|0) | **Interpretation:** A large goodwill component (vs. purely identifiable intangibles) often implies value was tied to expected synergies, growth expectations, or assembled workforce/going‑concern economics—not just separable IP. --- ## 7) Most recent disclosed trajectory: FY2025 preliminary results + FY2026 guidance (8‑K exhibit) GeneDx filed an 8‑K with a J.P. Morgan Healthcare Conference presentation (Exhibit 99.2) that contains unaudited preliminary FY2025 and FY2026 guidance. ### Preliminary Q4 & FY2025 (unaudited) | Metric | Q4 2025 | FY 2025 | |---|---:|---:| | Revenue | $121m ["Revenue2 $121 million"](0001818331-26-000005|2) | $427m ["$427 million"](0001818331-26-000005|2) | | Adjusted gross margin | 71% ["Adjusted gross margin2 71%"](0001818331-26-000005|2) | 71% ["71%"](0001818331-26-000005|2) | | Adjusted net income | Positive ["Adjusted net income2 Positive"](0001818331-26-000005|2) | Positive ["Positive"](0001818331-26-000005|2) | | Cash on hand | — | $172m ["Cash on hand $172 million"](0001818331-26-000005|2) | ### FY2026 guidance (company-provided) | Metric | FY2026 guidance | |---|---:| | Revenue | $540m–$555m ["Revenue $540 to $555 million"](0001818331-26-000005|2) | | Adjusted gross margin | ≥70% ["Adjusted gross margin1 At least 70%"](0001818331-26-000005|2) | | Adjusted net income | Positive ["Adjusted net income1 Positive"](0001818331-26-000005|2) | --- ## Bottom line: what Alpha Analyst would “watch” inside filings (without leaving filings) 1. **Revenue quality vs. volume growth:** keep tracking disclosures about *variable consideration*, reserve changes, and payor settlements—because those can swing reported revenue materially. ["variable consideration"](0001818331-23-000064|0) ["$30.1 million decrease"](0001818331-23-000064|0) 2. **Payor concentration drift:** the anonymized “Payor E” concentration is a tell—if concentration rises, reimbursement risk becomes more binary. ["Payor E 28%"](0001818331-23-000064|0) 3. **Regulatory “cost curve” from LDT rule:** the five-phase FDA timeline creates a calendar for potential compliance uplift and operational changes. ["five stages"](0001818331-25-000021|0) 4. **Supply-chain fragility:** a single supplier at ~14% of purchases is a quiet but real operational risk. ["One supplier accounted for approximately 14%"](0001818331-23-000064|0) 5. **Data flywheel credibility:** the phenotype + trio + “one million sequenced specimens” disclosures are the anchor claims behind their interpretation advantage. ["over 6 million structured phenotypes"](0001818331-25-000021|0) ["over one million sequenced specimens"](0001818331-25-000021|0) If you want a “next layer” deep dive, I can pull the *exact risk factor language* around reimbursement audits/recoupments and map it to the accounting mechanics (variable consideration) and the payor concentration table—still purely from filings.

## GeneDx (GeneDx Holdings Corp.) — a filings-first deep dive (with the “hard-to-find” stuff) **Executive takeaway:** GeneDx’s disclosed “moat” is less about a single test and more about (1) an internally built rare-disease knowledgebase/dataset (phenotype + trio structure) and (2) operational + reimbursement plumbing (portfolio-based revenue recognition, variable consideration, and payor-specific friction) that determines whether sequencing volume becomes durable cash flow. ["over 6 million structured phenotypes"](0001818331-25-000021|0) ["processed as parent-child trios"](0001818331-25-000021|0) ["updates estimated variable consideration quarterly"](0001818331-23-000064|0) --- ## 0) Quick “map” (jump-to sections) 1. **What GeneDx actually sells (in filings terms)** 2. **The “dataset moat” disclosed in 10-K (and why it’s hard to replicate)** 3. **Revenue mechanics that matter: payor mix, variable consideration, and reserve releases** *(filings gold)* 4. **Who really pays? Payor concentration + A/R signals** *(hard to find)* 5. **Regulatory stack: CLIA/CAP/state licensing + the FDA LDT rule timeline** *(hard to operationalize)* 6. **M&A/accounting tells: what they paid for in the GeneDx acquisition (intangible composition)** 7. **Most recent disclosed trajectory: preliminary FY2025 + FY2026 guide (8-K exhibit)** --- ## 1) What GeneDx “is” in filings language (what they do + who they bill) GeneDx describes itself as providing “genomics-related diagnostic and information services,” generating test reports for clinicians/patients and billing “third-party payors across the United States.” ["genomics-related diagnostic"](0001818331-23-000064|0) ["bills third-party payors"](0001818331-23-000064|0) In the more recent 10-K framing, their core commercialization thesis is that **exome/genome sequencing can replace “fragmented” panel testing** (they literally position WGS as “Just One Test”). ["repeated and fragmented testing"](0001818331-25-000021|0) ["Just One Test"](0001818331-25-000021|0) --- ## 2) The dataset moat — the *specific* disclosures worth noticing ### The two numbers that matter GeneDx discloses a dataset with: - **“over 6 million structured phenotypes”** and - **~60% of exomes/genomes processed as “parent-child trios.”** ["over 6 million structured phenotypes"](0001818331-25-000021|0) ["approximately 60%"](0001818331-25-000021|0) ["parent-child trios"](0001818331-25-000021|0) Why that’s unusually meaningful (and easy to miss in filings): - **Trio structure** is not just “more data”; it changes interpretability (you can infer inheritance patterns, de novo variants, etc.). GeneDx explicitly says they invested in sequencing parents because it can “provide additional diagnostic information” and “improv[e] the precision” of analysis. ["sequence the parents"](0001818331-25-000021|0) ["additional diagnostic information"](0001818331-25-000021|0) ["improving the precision"](0001818331-25-000021|0) ### The Medicaid angle (often overlooked) GeneDx claims it has “served the Medicaid population for nearly a decade ahead of the first state to enact health coverage for exome/genome,” using that to argue the dataset is “highly diversified” and matches U.S. demographics. ["served the Medicaid population"](0001818331-25-000021|0) ["highly diversified"](0001818331-25-000021|0) This is strategically important because payer mix affects: - **collections, denials, and retroactive adjustments** (see §3), and - whether “volume growth” translates into “revenue quality.” --- ## 3) Revenue mechanics that matter (and are genuinely “hard to find”) ### 3.1 Disaggregated revenue by payor channel (Q2’23 + 6M’23) Below is a filings-sourced view of how revenue breaks out (this kind of table often gets ignored, but it’s the skeleton of the business model). **Disaggregated revenue by payor category (USD millions)** | Period | Patients w/ third‑party insurance | Institutional customers | Self‑pay patients | Other revenue | Total | |---|---:|---:|---:|---:|---:| | **Q2 2023** | 30.573 ["30,573"](0001818331-23-000064|0) | 15.748 ["15,748"](0001818331-23-000064|0) | 0.314 ["314"](0001818331-23-000064|0) | 2.071 ["2,071"](0001818331-23-000064|0) | 48.706 ["48,706"](0001818331-23-000064|0) | | **Q2 2022** | 21.398 ["21,398"](0001818331-23-000064|0) | 11.120 ["11,120"](0001818331-23-000064|0) | 1.486 ["1,486"](0001818331-23-000064|0) | 2.165 ["2,165"](0001818331-23-000064|0) | 36.169 ["36,169"](0001818331-23-000064|0) | | **6M 2023** | 55.902 ["55,902"](0001818331-23-000064|0) | 31.808 ["31,808"](0001818331-23-000064|0) | 0.775 ["775"](0001818331-23-000064|0) | 3.360 ["3,360"](0001818331-23-000064|0) | 91.845 ["91,845"](0001818331-23-000064|0) | | **6M 2022** | 68.860 ["68,860"](0001818331-23-000064|0) | 15.151 ["15,151"](0001818331-23-000064|0) | 2.488 ["2,488"](0001818331-23-000064|0) | 3.611 ["3,611"](0001818331-23-000064|0) | 90.110 ["90,110"](0001818331-23-000064|0) | **What’s “hard” here:** In many diagnostics businesses, “revenue” is not the same as “cash collected,” and the mix between third‑party, institutional, and self‑pay typically drives days sales outstanding, denial work, and how much “true-up” revenue you see later. GeneDx effectively confirms this by explicitly pointing to the role of payor mix, reimbursement policies, collection history, and price concessions in diagnostic test revenue. ["depends on a number of factors"](0001818331-23-000064|0) ["payor mix"](0001818331-23-000064|0) ["historical collection experience"](0001818331-23-000064|0) ### 3.2 The hidden lever: “variable consideration” + quarter-to-quarter true-ups GeneDx says it determines transaction price **“on a portfolio basis when applicable”** and **updates estimated variable consideration quarterly**—this is a big deal because it means **reported revenue includes modeled/estimated reimbursement outcomes** that can later reverse. ["portfolio basis"](0001818331-23-000064|0) ["updates estimated variable consideration quarterly"](0001818331-23-000064|0) They disclose that in **Q2 2023** the quarterly change in estimate produced a **net $3.5 million increase to revenue** for tests whose performance obligation was satisfied in prior periods, tied to **“partial release of a third party payor reserve.”** ["net $3.5 million increase"](0001818331-23-000064|0) ["partial release"](0001818331-23-000064|0) ["payor reserve"](0001818331-23-000064|0) They also disclose the opposite case: **Q2 2022 had a net $30.1 million decrease** for prior-period tests, with **$24.2 million related to years ended Dec 31, 2021 and prior**—a very explicit signal that reimbursement/accounting adjustments can be *material* and can reach back multiple years. ["$30.1 million decrease"](0001818331-23-000064|0) ["$24.2 million"](0001818331-23-000064|0) ["December 31, 2021"](0001818331-23-000064|0) ### 3.3 “Certain payor matters” (the section many readers skip, but investors shouldn’t) GeneDx states that third‑party payors (including government programs) may deny payment or seek recoupment for tests they argue were improperly billed / not medically necessary / against coverage determinations, and that revenue may be “subject to retroactive adjustment.” ["seek to recoup"](0001818331-23-000064|0) ["subject to retroactive adjustment"](0001818331-23-000064|0) They also disclose a concrete remediation step: **in Q3 2022 they instituted a third‑party review of billing claims and compliance practices**, plus new policies/procedures and strengthening the billing compliance team. ["third-party review"](0001818331-23-000064|0) ["billing compliance"](0001818331-23-000064|0) --- ## 4) Who really pays? Payor concentration + receivables signals GeneDx defines “significant” payors as those >10% of revenue or A/R, and then actually provides a payor concentration table (with anonymized payors). ["represent more than 10%"](0001818331-23-000064|0) ### Payor concentration snapshot (from filings; anonymized payors) | Payor | Q2’23 Revenue % | Q2’22 Revenue % | 6M’23 Revenue % | 6M’22 Revenue % | A/R % @ 6/30/23 | A/R % @ 12/31/22 | |---|---:|---:|---:|---:|---:|---:| | Payor B | 14% ["14%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 14% ["14%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 14% ["14%"](0001818331-23-000064|0) | | Payor C | *<10% ["*less than 10%"](0001818331-23-000064|0) | 12% ["12%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 10% ["10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | | Payor D | *<10% ["*less than 10%"](0001818331-23-000064|0) | 10% ["10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 10% ["10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | | Payor E | 28% ["28%"](0001818331-23-000064|0) | 19% ["19%"](0001818331-23-000064|0) | 26% ["26%"](0001818331-23-000064|0) | *<10% ["*less than 10%"](0001818331-23-000064|0) | 15% ["15%"](0001818331-23-000064|0) | 14% ["14%"](0001818331-23-000064|0) | **Why this is a big analytical lever:** Payor E being **28% of quarterly revenue** is the kind of concentration that makes (a) contract terms, (b) medical policy shifts, and (c) audit behavior disproportionately impactful. ["Payor E"](0001818331-23-000064|0) ["28%"](0001818331-23-000064|0) ### A second “quiet” risk: supplier concentration The same filing discloses supplier concentration: **one supplier accounted for ~14% of purchases** (Q2’23 and 6M’23). ["One supplier accounted for approximately 14%"](0001818331-23-000064|0) That matters because lab operations are reagent- and instrument-dependent; supply disruption can hit turnaround time, COGS, and service levels. --- ## 5) Regulatory stack — what GeneDx must keep “green” to stay in business This is where filings give you operational truth (and where most casual research is weakest). ### 5.1 CLIA + CAP + state licensing (the must-have permissions) GeneDx states its laboratories are subject to **CLIA**, with requirements across operations/personnel/quality control and that CLIA is a prerequisite for billing Medicare/Medicaid and many commercial payors. ["subject to the Clinical Laboratory Improvement Amendments"](0001818331-25-000021|0) ["prerequisite to be eligible to bill"](0001818331-25-000021|0) They also disclose **CAP accreditation** at their Gaithersburg lab and that CMS relies on CAP surveys/inspections when CAP is the accrediting organization. ["accredited by the College of American Pathologists"](0001818331-25-000021|0) ["CMS does not perform"](0001818331-25-000021|0) State licensing: they explicitly list states where they maintain lab licenses, and highlight New York’s test‑specific approval requirement for LDTs. ["state laboratory licenses"](0001818331-25-000021|0) ["Maryland and in New York, California, Pennsylvania and Rhode Island"](0001818331-25-000021|0) ["approval on a test-specific basis"](0001818331-25-000021|0) ["New York Department of Health"](0001818331-25-000021|0) ### 5.2 The FDA’s LDT rule: a timeline investors can actually model GeneDx discloses that FDA published a **final rule on LDTs (April 29, 2024)** and lays out a **five‑phase plan** to end broad enforcement discretion over ~4 years, with key effective dates. ["April 29, 2024"](0001818331-25-000021|0) ["five stages"](0001818331-25-000021|0) **FDA LDT rule phase timeline (as GeneDx summarizes it)** | Phase | Effective date | What starts applying (high level) | |---|---|---| | Phase 1 | May 6, 2025 ["Phase 1 (effective May 6, 2025)"](0001818331-25-000021|0) | medical device adverse event reporting + correction/removal reporting + certain quality systems complaint handling ["adverse event"](0001818331-25-000021|0) | | Phase 2 | May 6, 2026 ["Phase 2 (effective May 6, 2026)"](0001818331-25-000021|0) | “all other device requirements” except remaining QSR + premarket review ["all other device requirements"](0001818331-25-000021|0) | | Phase 3 | May 6, 2027 ["Phase 3 (effective May 6, 2027)"](0001818331-25-000021|0) | remaining applicable quality system requirements ["all remaining applicable quality systems"](0001818331-25-000021|0) | | Phase 4 | Nov 6, 2027 ["Phase 4 (effective November 6, 2027)"](0001818331-25-000021|0) | premarket submissions for high‑risk tests (PMA) ["premarket submission requirements for high-risk tests"](0001818331-25-000021|0) | | Phase 5 | May 6, 2028 ["Phase 5 (effective May 6, 2028)"](0001818331-25-000021|0) | premarket submissions for moderate/low risk (de novo / 510(k)) ["moderate- and low-risk tests"](0001818331-25-000021|0) | GeneDx also flags that the rule “potentially extends enforcement discretion” for certain tests, explicitly including **LDTs approved by NY State DOH** and certain pre‑May 6, 2024 tests (with limitations). ["extends enforcement discretion"](0001818331-25-000021|0) ["approved by the New York State Department of Health"](0001818331-25-000021|0) ["first marketed prior to May 6, 2024"](0001818331-25-000021|0) **Why this matters:** This is an explicit roadmap for potential incremental compliance cost, process overhead, and possibly product rationalization—especially for companies whose menu is mostly LDTs. --- ## 6) The acquisition accounting tells: what they *actually bought* (intangible mix) From a 10‑Q disclosure, GeneDx provides the **Legacy GeneDx acquisition** purchase price allocation (a rare, very concrete look at what management believed the “value” was). **Legacy GeneDx acquisition — selected fair values (USD millions)** | Line item | Value | |---|---:| | Trade names & trademarks | 50.0 ["Trade names and trademarks"](0001818331-23-000064|0) | | Developed technology | 48.0 ["Developed technology"](0001818331-23-000064|0) | | Customer relationships | 98.0 ["Customer relationships"](0001818331-23-000064|0) | | Goodwill | 185.871 ["Goodwill"](0001818331-23-000064|0) | | Aggregate purchase price | 364.476 ["Aggregate purchase price"](0001818331-23-000064|0) | **Interpretation:** A large goodwill component (vs. purely identifiable intangibles) often implies value was tied to expected synergies, growth expectations, or assembled workforce/going‑concern economics—not just separable IP. --- ## 7) Most recent disclosed trajectory: FY2025 preliminary results + FY2026 guidance (8‑K exhibit) GeneDx filed an 8‑K with a J.P. Morgan Healthcare Conference presentation (Exhibit 99.2) that contains unaudited preliminary FY2025 and FY2026 guidance. ### Preliminary Q4 & FY2025 (unaudited) | Metric | Q4 2025 | FY 2025 | |---|---:|---:| | Revenue | $121m ["Revenue2 $121 million"](0001818331-26-000005|2) | $427m ["$427 million"](0001818331-26-000005|2) | | Adjusted gross margin | 71% ["Adjusted gross margin2 71%"](0001818331-26-000005|2) | 71% ["71%"](0001818331-26-000005|2) | | Adjusted net income | Positive ["Adjusted net income2 Positive"](0001818331-26-000005|2) | Positive ["Positive"](0001818331-26-000005|2) | | Cash on hand | — | $172m ["Cash on hand $172 million"](0001818331-26-000005|2) | ### FY2026 guidance (company-provided) | Metric | FY2026 guidance | |---|---:| | Revenue | $540m–$555m ["Revenue $540 to $555 million"](0001818331-26-000005|2) | | Adjusted gross margin | ≥70% ["Adjusted gross margin1 At least 70%"](0001818331-26-000005|2) | | Adjusted net income | Positive ["Adjusted net income1 Positive"](0001818331-26-000005|2) | --- ## Bottom line: what Alpha Analyst would “watch” inside filings (without leaving filings) 1. **Revenue quality vs. volume growth:** keep tracking disclosures about *variable consideration*, reserve changes, and payor settlements—because those can swing reported revenue materially. ["variable consideration"](0001818331-23-000064|0) ["$30.1 million decrease"](0001818331-23-000064|0) 2. **Payor concentration drift:** the anonymized “Payor E” concentration is a tell—if concentration rises, reimbursement risk becomes more binary. ["Payor E 28%"](0001818331-23-000064|0) 3. **Regulatory “cost curve” from LDT rule:** the five-phase FDA timeline creates a calendar for potential compliance uplift and operational changes. ["five stages"](0001818331-25-000021|0) 4. **Supply-chain fragility:** a single supplier at ~14% of purchases is a quiet but real operational risk. ["One supplier accounted for approximately 14%"](0001818331-23-000064|0) 5. **Data flywheel credibility:** the phenotype + trio + “one million sequenced specimens” disclosures are the anchor claims behind their interpretation advantage. ["over 6 million structured phenotypes"](0001818331-25-000021|0) ["over one million sequenced specimens"](0001818331-25-000021|0) If you want a “next layer” deep dive, I can pull the *exact risk factor language* around reimbursement audits/recoupments and map it to the accounting mechanics (variable consideration) and the payor concentration table—still purely from filings.